• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名接受达卡巴嗪（DTIC）治疗恶性黑色素瘤的患者出现肝衰竭。

Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.

作者信息

Frosch P J, Czarnetzki B M, Macher E, Grundmann E, Gottschalk I

出版信息

J Cancer Res Clin Oncol. 1979;95(3):281-6. doi: 10.1007/BF00410649.

DOI:10.1007/BF00410649
PMID:528568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12252948/
Abstract

A 55-year-old white woman received chemotherapy with DTIC after surgery for malignant melanoma (stage I, SSM IV, depth of invasion 12 mm). She died suddenly during the second treatment cycle. Autopsy revealed massive necrosis of the liver and thrombosis of the hepatic veins. The cause of the fatal outcome is attributed to the adverse toxic effects of DTIC.

摘要

一名55岁的白人女性在接受恶性黑色素瘤手术（I期，浅表扩散性黑色素瘤IV型，浸润深度12毫米）后接受了达卡巴嗪化疗。她在第二个治疗周期中突然死亡。尸检显示肝脏大面积坏死和肝静脉血栓形成。致命结果的原因归因于达卡巴嗪的不良毒性作用。

相似文献

1
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.一名接受达卡巴嗪（DTIC）治疗恶性黑色素瘤的患者出现肝衰竭。
J Cancer Res Clin Oncol. 1979;95(3):281-6. doi: 10.1007/BF00410649.
2
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].达卡巴嗪治疗恶性黑色素瘤。罕见的严重副作用：布加综合征（作者译）
Z Hautkr. 1982 Jul 1;57(13):971-80.
3
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].[达卡巴嗪治疗恶性黑色素瘤后发生布加综合征——一种可避免的并发症？]
Z Hautkr. 1985 Jun 15;60(12):961-72.
4
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?达卡巴嗪的致命性肝血管毒性。这真的是罕见事件吗？
Cancer. 1988 May 15;61(10):1988-91. doi: 10.1002/1097-0142(19880515)61:10<1988::aid-cncr2820611010>3.0.co;2-5.
5
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.急性肝营养不良伴肝静脉血栓形成：达卡巴嗪治疗的致命并发症。
Cancer Treat Rep. 1983 Sep;67(9):779-84.
6
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.达卡巴嗪（DTIC）治疗黑色素瘤后发生的肝静脉闭塞性疾病。
J Surg Oncol. 1984 Dec;27(4):268-70. doi: 10.1002/jso.2930270415.
7
Hepatic veno-occlusive disease due to DTIC.达卡巴嗪所致肝静脉闭塞病
Cancer. 1980 May 15;45(10):2670-4. doi: 10.1002/1097-0142(19800515)45:10<2670::aid-cncr2820451031>3.0.co;2-l.
8
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].恶性黑色素瘤氮烯咪胺治疗后出现的伴有急性肝营养不良的肝静脉闭塞综合征（作者译）
Klin Wochenschr. 1981 Mar 2;59(5):229-36. doi: 10.1007/BF01476580.
9
Allergy-induced hepatic toxicity associated with dacarbazine.与达卡巴嗪相关的过敏诱导的肝毒性。
Cancer Treat Rep. 1987 Feb;71(2):219-20.
10
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].达卡巴嗪（DTIC）治疗期间的布加综合征（作者译）
Dtsch Med Wochenschr. 1980 Feb 15;105(7):230-3. doi: 10.1055/s-2008-1070640.

引用本文的文献

1
Current status and perspectives in immunotherapy for metastatic melanoma.转移性黑色素瘤免疫治疗的现状与展望
Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23.
2
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.免疫检查点抑制剂伊匹木单抗联合达卡巴嗪用于日本初治、不可切除或转移性黑色素瘤患者的II期研究。
Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25.
3
A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma.单中心采用放射性栓塞作为葡萄膜黑色素瘤肝转移挽救治疗的经验。
Acta Radiol Open. 2015 Apr 6;4(4):2047981615570417. doi: 10.1177/2047981615570417. eCollection 2015 Apr.
4
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.依匹单抗的研发：一种用于治疗晚期黑色素瘤的新型免疫治疗方法。
Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
5
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.免疫疗法的最新进展如何改变转移性黑色素瘤患者的护理标准。
Ann Oncol. 2012 Sep;23 Suppl 8(Suppl 8):viii15-21. doi: 10.1093/annonc/mds258.
6
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.达卡巴嗪联合自体骨髓移植治疗实体瘤患者的I期临床及药理学研究
Invest New Drugs. 1993 May-Aug;11(2-3):169-79. doi: 10.1007/BF00874151.
7
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].恶性黑色素瘤氮烯咪胺治疗后出现的伴有急性肝营养不良的肝静脉闭塞综合征（作者译）
Klin Wochenschr. 1981 Mar 2;59(5):229-36. doi: 10.1007/BF01476580.
8
Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.药物对肝脏的影响。药物及药物相关肝病的最新表格汇编。
Dig Dis Sci. 1983 Jul;28(7):651-66. doi: 10.1007/BF01299927.
9
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.
Arch Dermatol Res. 1981;270(3):375-6. doi: 10.1007/BF00403944.
10
Clinical management of cytotoxic drug overdose.细胞毒性药物过量的临床管理。
Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):253-63. doi: 10.1007/BF03259938.

本文引用的文献

1
N-demethylation the antineoplastic agent4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide by rats and man.大鼠和人类对抗肿瘤药物4(5)-(3,3-二甲基-1-三氮烯)咪唑-5(4)-甲酰胺的N-去甲基化作用。
Cancer Res. 1970 Jan;30(1):147-50.
2
Combination phase 1-II study of imidazole carboxamide (NCS45388).咪唑甲酰胺（NCS45388）的1-2期联合研究
Oncology. 1972;26(2):310-6. doi: 10.1159/000224680.
3
Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis.抗肿瘤药物5(4)-(3,3-二甲基-1-三氮烯基)咪唑-4(5)-甲酰胺在枯草芽孢杆菌中的作用机制研究。
Biochem Pharmacol. 1970 Mar;19(3):911-9. doi: 10.1016/0006-2952(70)90254-6.
4
Chemotherapy of malignant melanoma.恶性黑色素瘤的化疗
Cancer. 1972 Dec;30(6):1604-15. doi: 10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5.
5
Mechanism of action and pharmacology studies with DTIC (NSC-45388).达卡巴嗪（NSC-45388）的作用机制及药理学研究
Cancer Treat Rep. 1976 Feb;60(2):149-52.
6
Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.急性白血病化疗后肝静脉闭塞病。两例报告。
Ann Intern Med. 1976 Nov;85(5):578-82. doi: 10.7326/0003-4819-85-5-578.
7
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.中央肿瘤学组中达卡巴嗪（NSC - 45388）的I期评估及其他恶性黑色素瘤研究
Cancer Treat Rep. 1976 Feb;60(2):183-7.
8
Results with methyl-CCNU and DTIC in metastatic melanoma.
Cancer. 1977 Sep;40(3):1010-5. doi: 10.1002/1097-0142(197709)40:3<1010::aid-cncr2820400308>3.0.co;2-c.
9
Hepatic-vein thrombosis after chemotherapy for histiocytoma.组织细胞增多症化疗后肝静脉血栓形成
Ann Intern Med. 1978 Apr;88(4):575-6. doi: 10.7326/0003-4819-88-4-575_2.
10
Photodegradation of dacarbazine.达卡巴嗪的光降解作用
Lancet. 1978 Sep 23;2(8091):681. doi: 10.1016/s0140-6736(78)92794-0.